How the EPO treats personalised healthcare patents

Personalised healthcare, or precision medicine, is an evolving field where a therapeutic treatment is tailored to an individual with a particular disease. The aim is to target the right treatment to the right patient, typically by using a diagnostic test (companion diagnostic test) for one or more biomarkers indicative of drug response.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Biotech

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Biotech

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

More features

UPC revives patent, but timing sinks Guardant’s appeal

HGF expands European offering with pair of in-house hires

Ashurst Perkins Coie opens its doors following landmark merger

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novo secures website blocking to tackle fake weight-loss drugs

Cooley Asia transactions duo make rival firm move

Insilico lands potential $2.5bn AI biotech partnership

How the EPO treats personalised healthcare patents

More on this story

Editor's picks

Editor's picks

More features